UCrest eyeing 10% revenue contribution from BRCATRUE distribution

January 22, 2018 | By | Reply More

Grab latest promotion at LAZADA now!

PETALING JAYA: Mobile health and cloud platform developer and provider UCrest Bhd is hoping to recognise a 10% contribution to its total revenue for the first few years, from the distribution of the BRCATRUE, an early breast and ovarian cancer detection genetic test kit.

Following a tie-up with US-based genetic test specialist Pathway Genomics, U Crest will serve as a distributor for its products in Southeast Asia, China, Taiwan and Russia.

UCrest CEO Eg Kah Yee said that the group is also working towards becoming a licensee to set up Pathway’s clinical laboratories in its existing market outside of Malaysia, for which China appears to be a primary choice.

At an EGM held today, the group received its shareholders approval for a private placement exercise involving up to 20% of its total share capital. It intends to raise up to RM42.76 million from the exercise.

FREE RM12.70 credit upon sign up to discover and book amazing travel experiences with Klook.

Category: News

About the Author ()

Leave a Reply